Connect with us

Technology

Get a Second Opinion Launches America’s First Pre‑Prescription Intelligence Platform

Published

on

DANVILLE, Calif., July 28, 2026 /PRNewswire/ — Get a Second Opinion today announced the nationwide debut of Pre‑Prescription Intelligence, a real‑time medication decision system that gives every patient clear visibility into efficacy, safety, interactions, and cost before a prescription is written. The platform delivers personalized guidance without requiring any personally identifiable information (PII), making it the first national‑scale medication intelligence system built for full anonymity. Free accounts are available at https://www.getasecondopinion.ai/

A New Standard for Pre‑Prescription Transparency

For the first time, Americans can understand their full medication regimen before treatment begins. Each personalized Second Opinion report ranks available options, translates FDA Drug Label content into plain English, highlights risks and contraindications, and provides clear next‑step guidance based on a patient’s unique non‑PII profile.

The public can also explore helpful articles covering more than 31,000 conditions and 14,000 medications, all freely accessible, no account required. With a free anonymous profile, individuals generate personalized Second Opinions in one click. Early results show strong impact: 97% of members find improved medication plans, and 93% discover lower-cost alternatives on their first use.

Cost and insurance visibility are built in. Patients see estimated monthly costs, coverage considerations, and plan‑specific factors to help avoid surprises and manage expenses.

“Patients deserve to be in control before they agree to treatment options – not after problems arise,” said Joel Ferman, CEO of Get a Second Opinion. “Pre‑Prescription Intelligence gives the public real‑time visibility into efficacy, safety, interactions, and cost. It restores independence, clarity, and confidence by translating clinical evidence into simple guidance patients can actually use to make informed decisions.”

Turning FDA Data Into Real‑Time Clinical Intelligence

Get a Second Opinion benchmarks every medication against FDA labeling and enhances it with additional clinical parameters, including data backed efficacy indicators, cautions, boxed warnings, contraindications, side‑effect profiles, market age, regulatory history, grouped generics and biosimilars, and interaction intelligence.

“Our breakthrough is converting massive, fragmented datasets into real‑time clinical intelligence,” said Andrew Ossipov, CTO of Get a Second Opinion. “By unifying thousands of regulatory records into a single meta‑analysis and enriching them with real‑world clinical parameters, we’ve built a high‑performance medication intelligence engine that sets a new technical standard for how pharmaceutical information should be used to benefit the public.”

Nationwide Medication Intelligence Infrastructure

Each medication is transformed into a comprehensive drug data card built from an average of 60 FDA records. Cards include enhanced clinical parameters, detailed side‑effect profiles, interaction indicators, and condition‑level comparisons across dozens of brands and alternatives. This creates the first nationwide system capable of analyzing a patient’s entire regimen – interactions, contraindications, and cost – before a prescription is written.

Enterprise Access

A secure Enterprise API is available for hospitals, research institutions, insurers, and health systems seeking real‑time medication intelligence at scale. The API supports clinical workflows, research environments, and care‑team decision support within existing regulatory frameworks.

About Get a Second Opinion

Get a Second Opinion improves medication outcomes by translating clinical evidence into clear, personalized guidance. The platform combines automated literature review, FDA label analysis, and pharmacoeconomic insights to deliver fast, actionable second opinions. Get a Second Opinion is sponsored by Google as an Ecosystem Partner and is part of the NVIDIA Inception Program.

View original content to download multimedia:https://www.prnewswire.com/news-releases/get-a-second-opinion-launches-americas-first-preprescription-intelligence-platform-302834785.html

SOURCE Get A Second Opinion Inc.

Continue Reading

Technology

Genedata Expands AI Discovery Workflows with NVIDIA BioNeMo Open Models, Including the New RFD4-Proteina Release

Published

on

By

Bringing next-generation binder design models into production discovery

BASEL, Switzerland, Oct. 22, 2026 /PRNewswire/ — Genedata, a Danaher company, and the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced the addition of the new RFD4-Proteina binder design model into Genedata’s AI-enabled discovery workflows, following the model’s introduction at NVIDIA GTC Berlin. As an early ecosystem partner, Genedata is among the first companies to make RFD4-Proteina available within its production discovery workflows. By connecting AI-generated molecular designs, scientific data, and laboratory results, Genedata helps researchers transform AI predictions into continuous learning cycles that accelerate biologics discovery.

The workflow begins with scientists defining target characteristics and required properties using Genedata’s AI co-scientist. NVIDIA’s open protein design models then generate and evaluate candidate binders within Genedata. As candidates move into laboratory testing, results are captured and linked back to the original designs, helping scientists refine and rank the next round.

“Advances in AI are creating unprecedented opportunities for protein and antibody discovery, but unlocking their full value requires more than access to powerful models alone,” said Othmar Pfannes, Ph.D., President of Genedata. “Researchers need a way to connect molecular design, experimental execution, and scientific data into a continuous learning process. Genedata serves as the digital backbone that brings these elements together, helping scientists evaluate more candidates before testing, preserve the scientific context behind each outcome, and build knowledge from one discovery cycle to the next.”

While advances in generative AI are rapidly expanding what scientists can design, many organizations still struggle to operationalize these models within production scientific research workflows. Genedata provides the orchestration, governance, and scientific data foundation needed to deploy NVIDIA BioNeMo open models, including RFD4-Proteina, directly within the discovery workflows scientists use every day. Researchers can apply AI-generated designs within established processes while maintaining lineage, traceability, and scientific context across the discovery lifecycle.

Within Danaher’s autonomous laboratory initiative, these capabilities connect AI, automation, and scientific data in a closed-loop discovery framework where each experimental outcome informs the next design cycle, creating a continuous learn-and-improve process that advances science while keeping scientists in control.

About Genedata
Genedata, a Danaher company and the leading provider of enterprise software solutions for biopharma R&D, transforms biopharma data into intelligence. Our innovative solutions combine deep science, technology, and AI domain knowledge. Leading biopharma organizations and cutting-edge biotechs partner with Genedata to digitalize and automate complex data workflows. Our advanced analytics and embedded AI enable data-driven decisions. From early discovery through development to the clinic, Genedata solutions drive innovation and maximize ROI being trusted by customers worldwide for more than 25 years.

www.genedata.com
LinkedIn | YouTube

About Danaher
Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Through our connected ecosystem of industry-leading businesses, we work side by side with customers to solve their most complex scientific and clinical challenges—helping move innovations from discovery to delivery faster for patients who depend on them. Powered by the Danaher Business System, our advanced science and technology and proven ability to innovate help enable faster, more accurate diagnoses and reduce the time, cost, and risk required to discover, develop, and deliver life-changing therapies. Through continuous improvement and operational excellence, our approximately 60,000 associates worldwide are focused on delivering lasting impact and improving quality of life around the world, while building a healthier, more sustainable tomorrow. Explore more at www.danaher.com.

Disclaimer

The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company’s products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

All product and service names mentioned are the trademarks of their respective companies.

View original content to download multimedia:https://www.prnewswire.com/news-releases/genedata-expands-ai-discovery-workflows-with-nvidia-bionemo-open-models-including-the-new-rfd4-proteina-release-302915726.html

SOURCE Genedata

Continue Reading

Technology

Bybit AI Empowers Users with Their Personal Financial Edge, Adding Personalization and Memory

Published

on

By

DUBAI, UAE, Oct. 22, 2026 /PRNewswire/ — Bybit, the New Financial Platform trusted by more than 80 million users worldwide, has announced new personalization and memory features for Bybit AI, its in-app intelligent conversational layer. Bybit AI now builds a profile from each user’s assets, positions, behavior and risk profile, connecting wealth, markets and trading across the Bybit ecosystem.

Launched in September, Bybit AI organically unifies Bybit’s core services within a single chat interface. The newly added features extend its capacity from responding to individual requests to maintaining a continuous understanding of the user, giving each user their personal financial edge.

Putting the user at the center, Bybit AI is evolving on three pillars:

Personalized: With permissions granted and limits set, Bybit AI analyzes actual account information, including financial behavior and risk profile alongside assets and positions, to generate outputs tailored to the individual.Connected: Bybit AI links Markets, Trading, Earn, Card and other Bybit products, drawing on the full picture of a user’s holdings and activity rather than a single product.Remembered: Users can proactively share their preferences with Bybit AI, which retains this context through long-term memory so that each conversation builds on the previous one.

The release also introduces Featured, a set of customized entry points for specific use cases. Each entry point offers predefined prompts, such as generating a wealth management plan based on a user’s assets and risk tolerance, and returns structured analysis with key data, clear insights and suggested next steps.

Bybit AI supports main account operations while giving users the option to deploy it within a dedicated Bybit AI sub-account. The AI-powered assistant is built on a security-first architecture. Outputs are provided for informational purposes only and do not constitute investment advice. Instructions are executed in chats only after customer authorizations.

Bybit expects to introduce further updates to Bybit AI as it continues to build toward AI-native financial services, with conversational intelligence positioned as core infrastructure.

To explore Bybit AI and learn more about how it works, users may visit: Bybit AI  – Learn how to use Bybit through conversation.

#Bybit  / #NewFinancialPlatform 

About Bybit

Bybit is The New Financial Platform.

We believe every person should have access to every financial opportunity on earth. That’s why we’re building the first intelligent platform that connects anyone, anywhere to the world’s finance.

Trusted by more than 80 million users worldwide, Bybit brings together investing, trading, payments, and wealth-building in a single secure and intelligent ecosystem. Through the combination of AI-powered technology, deep global liquidity, robust security, and transparent operations, Bybit makes global finance more accessible, efficient, and empowering for everyone.

Built for everyone. Powered by intelligence. Open to the world.

Learn more at Bybit.com.

For more details about Bybit, please visit Bybit Press

For media inquiries, please contact: media@bybit.com

For updates, please follow: Bybit’s Communities and Social Media

Facebook | Instagram | LinkedIn | Reddit | Telegram | TikTok | X | Youtube

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/bybit-ai-empowers-users-with-their-personal-financial-edge-adding-personalization-and-memory-302916350.html

Continue Reading

Technology

Poq is now a Shopify Certified Technology Partner

Published

on

By

LONDON, Oct. 22, 2026 /PRNewswire/ —  poq, the native mobile app platform for retail brands, today announced it has been recognised as a Shopify Certified Technology Partner. Shopify’s certification is reserved for app partners that meet Shopify’s standards for quality, security, performance and support. poq is now listed in the Shopify Technology Partner Directory and the Certified Technology Partner App Store Collection, making it easier for enterprise Shopify merchants to find and adopt a proven native app platform.

poq already powers native iOS and Android apps for joint customers including Ardene, Steve Madden UK, e.l.f. Beauty (globally), Horze (pan-European), Mamas & Papas (UK) and ECO. Modern Essentials (ANZ and UK). Across the poq platform, shoppers convert at 1.8 times the rate of mobile web, based on the median across 21 brands from January 2025 to January 2026.

“Certification from Shopify is independent validation that poq meets the high standard Shopify sets for its technology partners,” said Jay Johnston, CEO of poq. “Our customers use their apps to build loyalty and drive repeat purchases from their most valuable shoppers. This recognition means more Shopify merchants can launch a high-performing native app with confidence, on a platform already proven at scale across four continents.”

Results for Shopify Brands

European equestrian retailer Horze moved to Shopify and chose to stay with poq for its native app. “After choosing to continue working together, I can confidently say that this was absolutely the right decision. The level of motivation, ownership, and commitment the poq team demonstrated throughout the project was truly impressive,” said Dominik Schlag, CFO of Horze.

In the UK, Mamas & Papas uses its poq app to make shopping easier for busy parents. “Our poq app makes shopping with us quick and easy wherever they are, and drives loyalty and repeat purchases,” said Jo Molineux, Digital Director at Mamas & Papas.

About poq

poq is a leading Software-as-a-Service (SaaS) platform that empowers retailers and brands to create and maintain engaging, high-performance native mobile apps. With a focus on driving customer engagement and revenue, poq’s platform enables seamless integration, powerful personalisation, and an enhanced shopping experience for businesses worldwide. Learn more at poqcommerce.com.

Media contact
Emma Williams, Marketing Lead
emma.williams@poqcommerce.com  

View original content to download multimedia:https://www.prnewswire.com/news-releases/poq-is-now-a-shopify-certified-technology-partner-302915873.html

SOURCE Poq

Continue Reading

Trending